wet macular degeneration
wet macular degeneration
Explore linked clinical trials. Standard reference: MONDO:000541727 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT07440225 | |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-09-24 | NCT07482176 | |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Geographic Atrophy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, age-related macular degeneration, eye disorder, macular degeneration, nervous system disorder, retinal degeneration, retinal disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 2 | 2026-09-22 | NCT05230537 | |
| A Phase 2 Study of NT-101 Topical in Patients With Wet AMD | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 2 | 2026-09-16 | NCT07811726 | |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Not yet recruiting | Phase 3 | 2026-09-11 | NCT07816315 | |
| Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-09-11 | NCT04663750 | |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-10 | NCT05984927 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06683742 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06668064 | |
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05197270 | |
| LEAP Strategy for Neovascular Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Not yet recruiting | Not applicable | 2026-08-19 | NCT07744204 | |
| Evaluation of PAN-90806 Eye Drops in Healthy Subjects | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Not yet recruiting | Phase 1 | 2026-08-14 | NCT07764965 | |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) | Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Recruiting | Phase 2 / Phase 3 | 2026-08-06 | NCT07496567 | |
| Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) | wet macular degeneration | Recruiting | Phase 3 | 2026-08-06 | NCT07317934 | |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-08-03 | NCT05407636 | |
| Stem Cell Ophthalmology Treatment Study II | Abnormalities, Multiple, CNS demyelinating autoimmune disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cranial Nerve Injuries, Craniocerebral Trauma, Deaf-Blind Disorders, Deafness, Doyne honeycomb retinal dystrophy, Ear Diseases, Eye Diseases, Hereditary, Geographic Atrophy, Hearing Loss, Sensorineural, Leber hereditary optic neuropathy, Neurologic Manifestations, Nutritional and Metabolic Diseases, Optic Atrophy, Autosomal Dominant, Optic Neuropathy, Ischemic, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Stargardt disease, Usher syndrome, Vision, Low, acute transverse myelitis, age-related macular degeneration, autoimmune disease, autoimmune disorder of the nervous system, blindness (disorder), cardiovascular disorder, cone dystrophy, cone-rod dystrophy, cranial nerve neuropathy, demyelinating disease, eye disorder, glaucoma, hearing disorder, hearing loss disorder, hereditary disease, hereditary optic atrophy, immune system disorder, inborn mitochondrial metabolism disorder, inherited neurodegenerative disorder, inherited retinal dystrophy, injury, macular degeneration, metabolic disease, nervous system disorder, nervous system injury, neurodegenerative disease, neuromyelitis optica, nutritional deficiency disease, nutritional disorder, ocular hypertension, optic atrophy, optic nerve disorder, optic neuritis, otorhinolaryngologic disease, retinal degeneration, retinal disorder, retinitis pigmentosa, traumatic optic neuropathy, vascular disorder, vision disorder, vitamin A deficiency, vitamin deficiency disorder, wet macular degeneration | Recruiting | Not applicable | 2026-06-29 | NCT03011541 | |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-06-01 | NCT06864988 | |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06856577 | |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-28 | NCT04704921 | |
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | Embolism and Thrombosis, Venous Thrombosis, age-related macular degeneration, cardiovascular disorder, diabetic macular edema, eye disorder, macular degeneration, retinal degeneration, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-04-22 | NCT05112861 | |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-04-16 | NCT07064759 | |
| MMP-9 Inhibition for Recalcitrant Wet AMD | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 2 | 2026-04-02 | NCT04504123 | |
| Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), choroidal neovascularization, eye disorder, macular degeneration, nervous system disorder, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, vision disorder, wet macular degeneration | Active, not recruiting | Not stated | 2026-02-10 | NCT04645212 | |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] | Metaplasia, Neovascularization, Pathologic, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), choroidal neovascularization, eye disorder, macular degeneration, nervous system disorder, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 2 | 2025-08-22 | NCT05536973 | |
| Optimizing the Treatment Strategy for Age-related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Not applicable | 2025-06-08 | NCT04420923 |